Indeed, in a study using various syngeneic murine subcutaneous tumor models, G47Δ and systemic anti-CTLA-4 antibody administration enhanced antitumor activity with upregulation of gene signatures related to inflammation, lymphoid lineage, and T cell activation suggesting an increase in immune susceptibility47. The gene discussed is CTLA4; the disease is neoplasm.